{"id":"https://openalex.org/W1908996792","doi":"https://doi.org/10.1124/jpet.115.225748","title":"A Novel Modulator of Kv3 Potassium Channels Regulates the Firing of Parvalbumin-Positive Cortical Interneurons","display_name":"A Novel Modulator of Kv3 Potassium Channels Regulates the Firing of Parvalbumin-Positive Cortical Interneurons","publication_year":2015,"publication_date":"2015-06-17","ids":{"openalex":"https://openalex.org/W1908996792","doi":"https://doi.org/10.1124/jpet.115.225748","mag":"1908996792","pmid":"https://pubmed.ncbi.nlm.nih.gov/26085652"},"language":"en","primary_location":{"id":"doi:10.1124/jpet.115.225748","doi":"https://doi.org/10.1124/jpet.115.225748","is_oa":false,"landing_page_url":"https://doi.org/10.1124/jpet.115.225748","pdf_url":null,"source":{"id":"https://openalex.org/S102125482","display_name":"Journal of Pharmacology and Experimental Therapeutics","issn_l":"0022-3565","issn":["0022-3565","1521-0103"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310316283","host_organization_name":"American Society for Pharmacology and Experimental Therapeutics","host_organization_lineage":["https://openalex.org/P4310316283"],"host_organization_lineage_names":["American Society for Pharmacology and Experimental Therapeutics"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Pharmacology and Experimental Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001082605","display_name":"Marcelo D. Rosato\u2010Siri","orcid":"https://orcid.org/0000-0002-8848-7233","observed_orcids":["https://orcid.org/0000-0002-8848-7233"]},"institutions":[{"id":"https://openalex.org/I4210128413","display_name":"GlaxoSmithKline (Italy)","ror":"https://ror.org/03fe56089","country_code":"IT","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210128413"]},{"id":"https://openalex.org/I4210142740","display_name":"Aptuit (Italy)","ror":"https://ror.org/04xfypm71","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210142740"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","IT"],"is_corresponding":false,"raw_author_name":"Marcelo D. Rosato-Siri","raw_affiliation_strings":["Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I4210128413","https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","institution_ids":["https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","institution_ids":[]},{"raw_affiliation_string":"Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)","institution_ids":["https://openalex.org/I4210128413"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091775622","display_name":"Erika Zambello","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128413","display_name":"GlaxoSmithKline (Italy)","ror":"https://ror.org/03fe56089","country_code":"IT","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210128413"]},{"id":"https://openalex.org/I4210142740","display_name":"Aptuit (Italy)","ror":"https://ror.org/04xfypm71","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210142740"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","IT"],"is_corresponding":false,"raw_author_name":"Erika Zambello","raw_affiliation_strings":["Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I4210128413","https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","institution_ids":["https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","institution_ids":[]},{"raw_affiliation_string":"Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)","institution_ids":["https://openalex.org/I4210128413"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076093135","display_name":"Chiara Mutinelli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128413","display_name":"GlaxoSmithKline (Italy)","ror":"https://ror.org/03fe56089","country_code":"IT","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210128413"]},{"id":"https://openalex.org/I4210142740","display_name":"Aptuit (Italy)","ror":"https://ror.org/04xfypm71","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210142740"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","IT"],"is_corresponding":false,"raw_author_name":"Chiara Mutinelli","raw_affiliation_strings":["Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I4210128413","https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","institution_ids":["https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","institution_ids":[]},{"raw_affiliation_string":"Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)","institution_ids":["https://openalex.org/I4210128413"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077547813","display_name":"Nicoletta Garbati","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128413","display_name":"GlaxoSmithKline (Italy)","ror":"https://ror.org/03fe56089","country_code":"IT","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210128413"]},{"id":"https://openalex.org/I4210142740","display_name":"Aptuit (Italy)","ror":"https://ror.org/04xfypm71","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210142740"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","IT"],"is_corresponding":false,"raw_author_name":"Nicoletta Garbati","raw_affiliation_strings":["Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I4210128413","https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","institution_ids":["https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","institution_ids":[]},{"raw_affiliation_string":"Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)","institution_ids":["https://openalex.org/I4210128413"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072571336","display_name":"Roberto Benedetti","orcid":"https://orcid.org/0009-0007-8583-626X","observed_orcids":["https://orcid.org/0009-0007-8583-626X"]},"institutions":[{"id":"https://openalex.org/I4210128413","display_name":"GlaxoSmithKline (Italy)","ror":"https://ror.org/03fe56089","country_code":"IT","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210128413"]},{"id":"https://openalex.org/I4210142740","display_name":"Aptuit (Italy)","ror":"https://ror.org/04xfypm71","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210142740"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","IT"],"is_corresponding":false,"raw_author_name":"Roberto Benedetti","raw_affiliation_strings":["Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I4210128413","https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","institution_ids":["https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","institution_ids":[]},{"raw_affiliation_string":"Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)","institution_ids":["https://openalex.org/I4210128413"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009945328","display_name":"Laura Aldegheri","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128413","display_name":"GlaxoSmithKline (Italy)","ror":"https://ror.org/03fe56089","country_code":"IT","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210128413"]},{"id":"https://openalex.org/I4210142740","display_name":"Aptuit (Italy)","ror":"https://ror.org/04xfypm71","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210142740"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","IT"],"is_corresponding":false,"raw_author_name":"Laura Aldegheri","raw_affiliation_strings":["Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I4210128413","https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","institution_ids":["https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","institution_ids":[]},{"raw_affiliation_string":"Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)","institution_ids":["https://openalex.org/I4210128413"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Francesca Graziani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128413","display_name":"GlaxoSmithKline (Italy)","ror":"https://ror.org/03fe56089","country_code":"IT","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210128413"]},{"id":"https://openalex.org/I4210142740","display_name":"Aptuit (Italy)","ror":"https://ror.org/04xfypm71","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210142740"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","IT"],"is_corresponding":false,"raw_author_name":"Francesca Graziani","raw_affiliation_strings":["Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I4210128413","https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","institution_ids":["https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","institution_ids":[]},{"raw_affiliation_string":"Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)","institution_ids":["https://openalex.org/I4210128413"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109341304","display_name":"Caterina Virginio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128413","display_name":"GlaxoSmithKline (Italy)","ror":"https://ror.org/03fe56089","country_code":"IT","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210128413"]},{"id":"https://openalex.org/I4210142740","display_name":"Aptuit (Italy)","ror":"https://ror.org/04xfypm71","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210142740"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","IT"],"is_corresponding":false,"raw_author_name":"Caterina Virginio","raw_affiliation_strings":["Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I4210128413","https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","institution_ids":["https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","institution_ids":[]},{"raw_affiliation_string":"Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)","institution_ids":["https://openalex.org/I4210128413"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103806450","display_name":"Giuseppe S. Alvaro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128413","display_name":"GlaxoSmithKline (Italy)","ror":"https://ror.org/03fe56089","country_code":"IT","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210128413"]},{"id":"https://openalex.org/I4210142740","display_name":"Aptuit (Italy)","ror":"https://ror.org/04xfypm71","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210142740"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","IT"],"is_corresponding":false,"raw_author_name":"Giuseppe Alvaro","raw_affiliation_strings":["Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I4210128413","https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","institution_ids":["https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","institution_ids":[]},{"raw_affiliation_string":"Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)","institution_ids":["https://openalex.org/I4210128413"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5037742036","display_name":"Charles H. Large","orcid":"https://orcid.org/0000-0001-9814-7737","observed_orcids":["https://orcid.org/0000-0001-9814-7737"]},"institutions":[{"id":"https://openalex.org/I4210128413","display_name":"GlaxoSmithKline (Italy)","ror":"https://ror.org/03fe56089","country_code":"IT","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210128413"]},{"id":"https://openalex.org/I4210142740","display_name":"Aptuit (Italy)","ror":"https://ror.org/04xfypm71","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210142740"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","IT"],"is_corresponding":false,"raw_author_name":"Charles H. Large","raw_affiliation_strings":["Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.) charles.large@autifony.com","Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.) charles.large@autifony.com","institution_ids":["https://openalex.org/I4210128413","https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.)","institution_ids":["https://openalex.org/I4210142740"]},{"raw_affiliation_string":"Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.)","institution_ids":[]},{"raw_affiliation_string":"Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.)","institution_ids":["https://openalex.org/I4210128413"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3750,"currency":"USD","value_usd":3750},"apc_paid":null,"fwci":1.6152,"has_fulltext":false,"cited_by_count":66,"citation_normalized_percentile":{"value":0.82905658,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"354","issue":"3","first_page":"251","last_page":"260"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10493","display_name":"Ion channel regulation and function","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10493","display_name":"Ion channel regulation and function","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10581","display_name":"Neural dynamics and brain function","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2805","display_name":"Cognitive Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/kv3-potassium-channels","display_name":"Kv3 potassium channels","score":0.9710000157356262},{"id":"https://openalex.org/keywords/kv3-1","display_name":"Kv3.1","score":0.9210000038146973},{"id":"https://openalex.org/keywords/parvalbumin-positive-interneurons","display_name":"parvalbumin interneurons","score":0.9649999737739563},{"id":"https://openalex.org/keywords/somatosensory-cortex","display_name":"somatosensory cortex","score":0.9559999704360962},{"id":"https://openalex.org/keywords/tetraethylammonium","display_name":"tetraethylammonium","score":0.8289999961853027},{"id":"https://openalex.org/keywords/4-aminopyridine","display_name":"4-aminopyridine","score":0.8399999737739563},{"id":"https://openalex.org/keywords/corticolimbic-circuits","display_name":"corticolimbic circuits","score":0.781000018119812},{"id":"https://openalex.org/keywords/inhibitory-feedback","display_name":"inhibitory feedback","score":0.6320000290870667},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.7590000033378601},{"id":"https://openalex.org/keywords/neural-oscillations","display_name":"neural oscillations","score":0.5059999823570251}],"concepts":[{"id":"https://openalex.org/C141547260","wikidata":"https://www.wikidata.org/wiki/Q2720322","display_name":"Parvalbumin","level":2,"score":0.9061543941497803},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.5959489345550537},{"id":"https://openalex.org/C2983650178","wikidata":"https://www.wikidata.org/wiki/Q75839","display_name":"Cortical neurons","level":2,"score":0.5047262907028198},{"id":"https://openalex.org/C83743174","wikidata":"https://www.wikidata.org/wiki/Q423778","display_name":"Potassium channel","level":2,"score":0.5021626949310303},{"id":"https://openalex.org/C517785266","wikidata":"https://www.wikidata.org/wiki/Q703","display_name":"Potassium","level":2,"score":0.4586411118507385},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.42085760831832886},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.31062763929367065},{"id":"https://openalex.org/C12554922","wikidata":"https://www.wikidata.org/wiki/Q7100","display_name":"Biophysics","level":1,"score":0.2979249358177185},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000200","descriptor_name":"Action Potentials","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D000200","descriptor_name":"Action Potentials","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002460","descriptor_name":"Cell Line","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003412","descriptor_name":"Cricetulus","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007395","descriptor_name":"Interneurons","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D007395","descriptor_name":"Interneurons","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D008810","descriptor_name":"Mice, Inbred C57BL","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008822","descriptor_name":"Mice, Transgenic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010320","descriptor_name":"Parvalbumins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D013003","descriptor_name":"Somatosensory Cortex","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013003","descriptor_name":"Somatosensory Cortex","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016466","descriptor_name":"CHO Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019789","descriptor_name":"Tetraethylammonium","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051670","descriptor_name":"Shaw Potassium Channels","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D054852","descriptor_name":"Small Molecule Libraries","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1124/jpet.115.225748","doi":"https://doi.org/10.1124/jpet.115.225748","is_oa":false,"landing_page_url":"https://doi.org/10.1124/jpet.115.225748","pdf_url":null,"source":{"id":"https://openalex.org/S102125482","display_name":"Journal of Pharmacology and Experimental Therapeutics","issn_l":"0022-3565","issn":["0022-3565","1521-0103"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310316283","host_organization_name":"American Society for Pharmacology and Experimental Therapeutics","host_organization_lineage":["https://openalex.org/P4310316283"],"host_organization_lineage_names":["American Society for Pharmacology and Experimental Therapeutics"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Pharmacology and Experimental Therapeutics","raw_type":"journal-article"},{"id":"pmid:26085652","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26085652","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of pharmacology and experimental therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.1011.2392","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.1011.2392","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://jpet.aspetjournals.org/content/354/3/251.full.pdf","raw_type":"text"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.1011.650","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.1011.650","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://jpet.aspetjournals.org/content/early/2015/06/17/jpet.115.225748.full.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.5683000087738037,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W1485442548","https://openalex.org/W1487102420","https://openalex.org/W1531455680","https://openalex.org/W1747998245","https://openalex.org/W1794934403","https://openalex.org/W1898373063","https://openalex.org/W1964276320","https://openalex.org/W1970292539","https://openalex.org/W1991845725","https://openalex.org/W1997293666","https://openalex.org/W1998990346","https://openalex.org/W2001954021","https://openalex.org/W2009074192","https://openalex.org/W2013413397","https://openalex.org/W2018625865","https://openalex.org/W2021704663","https://openalex.org/W2034132958","https://openalex.org/W2071366993","https://openalex.org/W2078138394","https://openalex.org/W2079131863","https://openalex.org/W2079291010","https://openalex.org/W2079908682","https://openalex.org/W2096006516","https://openalex.org/W2097480079","https://openalex.org/W2099587101","https://openalex.org/W2103592460","https://openalex.org/W2108696245","https://openalex.org/W2124793944","https://openalex.org/W2126468386","https://openalex.org/W2134351637","https://openalex.org/W2149561999","https://openalex.org/W2152000284","https://openalex.org/W2160087707","https://openalex.org/W2252824017"],"related_works":["https://openalex.org/W7098907393","https://openalex.org/W2315133977","https://openalex.org/W2609003178","https://openalex.org/W2336693913","https://openalex.org/W2591230564","https://openalex.org/W1898373063","https://openalex.org/W7171932069","https://openalex.org/W1747998245","https://openalex.org/W1794934403","https://openalex.org/W4403047013"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":8},{"year":2025,"cited_by_count":8},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":3}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}